Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652957 | 1.00 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCYP3A4TSHR | |
| SCHEMBL13896366 | 0.95 | ADRB3 (0.49) | ADRB3ADRA2BADRA2C | |
| SCHEMBL14001907 | 0.93 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4TSHR | |
| SCHEMBL13896349 | 0.92 | ADRB3 (0.47) | ADRB3ADRA2BADRA2C | |
| SCHEMBL13886255 | 0.91 | ADRB3 (0.53) | ADRB3ADRA2BADRA2CCYP3A4TSHR | |
| SCHEMBL7876742 | 0.90 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL5534012 | 0.90 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL5530647 | 0.90 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL5530641 | 0.90 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL5534015 | 0.90 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951773-B2 | For treatment of hepatitis C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| EP-1934243-B1 | RING-CLOSING METATHESIS PROCESS FOR THE PREPARATION OF MACROCYCLIC PEPTIDES | BOEHRINGER INGELHEIM INT (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20080242835-A1 | Ring-Closing Metathesis Process for the Preparation of Macrocyclic Peptides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-02 | — | — | US | disclosed |
| WO-2007030656-A1 | RING-CLOSING METATHESIS PROCESS FOR THE PREPARATION OF MACROCYCLIC PEPTIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242835-A1 | Ring-Closing Metathesis Process for the Preparation of Macrocyclic Peptides | VIP, NGLY1, HPN | ADRB3 4386/4885ADRA2B 4715/4885ADRA2C 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.